Strong Sales Of Drugs, Vaccines, Propel Merck In 3Q
Strong Sales Of Drugs, Vaccines, Propel Merck In 3Q
Merck & Co. is reporting thirdquarter earnings of $2.94 billion on some very strong sales.

KENILWORTH, N.J.: Merck & Co. is reporting third-quarter earnings of $2.94 billion on some very strong sales.

The Kenilworth, New Jersey, company on Tuesday reported a profit of $1.16 per share. Earnings, adjusted for non-recurring costs and costs related to mergers and acquisitions, came to $1.74 per share.

That easily topped Wall Street expectations for earnings of $1.44 per share, according to a survey of analysts by Zacks Investment Research.

Revenue of $12.55 billion, also easily beating analyst projections for $12.26 billion.

Merck expects full-year earnings in the range of $5.91 to $6.01 per share, with revenue in the range of $47.6 billion to $48.6 billion.

Merck shares have dropped 13% since the beginning of the year, while the Standard & Poors 500 index has climbed slightly more than 5%. The stock has declined 4.5% in the last 12 months.

_____

A portion of this story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MRK at https://www.zacks.com/ap/MRK

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Read all the Latest News and Breaking News here

What's your reaction?

Comments

https://lamidix.com/assets/images/user-avatar-s.jpg

0 comment

Write the first comment for this!